Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 1
1983 2
1984 3
1985 2
1986 4
1987 3
1988 1
1989 1
1990 1
1991 2
1992 4
1993 6
1994 9
1995 16
1996 6
1997 18
1998 9
1999 12
2000 19
2001 9
2002 21
2003 40
2004 60
2005 62
2006 82
2007 100
2008 116
2009 161
2010 204
2011 205
2012 220
2013 262
2014 279
2015 366
2016 401
2017 426
2018 447
2019 504
2020 570
2021 588
2022 738
2023 94
Text availability
Article attribute
Article type
Publication date

Search Results

5,380 results
Results by year
Filters applied: . Clear all
Page 1
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N, O'Brien SM, Tam CS, Qiu L, Zhou K, Simkovic M, Mayer J, Gillespie-Twardy A, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Salmi T, Wang MD, Fu L, Li J, Wu K, Cohen A, Shadman M. Brown JR, et al. Among authors: qiu l. N Engl J Med. 2023 Jan 26;388(4):319-332. doi: 10.1056/NEJMoa2211582. Epub 2022 Dec 13. N Engl J Med. 2023. PMID: 36511784 Clinical Trial.
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
Hillmen P, Eichhorst B, Brown JR, Lamanna N, O'Brien SM, Tam CS, Qiu L, Kazmierczak M, Zhou K, Šimkovič M, Mayer J, Gillespie-Twardy A, Shadman M, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Österborg A, Yimer HA, Salmi T, Ji M, Yecies J, Idoine A, Wu K, Huang J, Jurczak W. Hillmen P, et al. Among authors: qiu l. J Clin Oncol. 2022 Nov 17:JCO2200510. doi: 10.1200/JCO.22.00510. Online ahead of print. J Clin Oncol. 2022. PMID: 36395435
Shell-Isolated Nanoparticle-Enhanced Electrochemiluminescence.
Lin LH, Wang JY, You CY, Qiu LH, Lin JS, Zhang FL, Yang ZL, Zhang YJ, Chen X, Li JF. Lin LH, et al. Among authors: qiu lh. Small. 2022 Sep;18(39):e2203513. doi: 10.1002/smll.202203513. Epub 2022 Aug 25. Small. 2022. PMID: 36008122
CTLs: Killers of intracellular bacteria.
Tian L, Zhou W, Wu X, Hu Z, Qiu L, Zhang H, Chen X, Zhang S, Lu Z. Tian L, et al. Among authors: qiu l. Front Cell Infect Microbiol. 2022 Oct 26;12:967679. doi: 10.3389/fcimb.2022.967679. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36389159 Free PMC article. Review.
Aptamer-Based Cancer Cell Analysis and Treatment.
Wu L, Zhang Y, Wang Z, Zhang Y, Zou J, Qiu L. Wu L, et al. Among authors: qiu l. ChemistryOpen. 2022 Oct;11(10):e202200141. doi: 10.1002/open.202200141. ChemistryOpen. 2022. PMID: 36264016 Free PMC article. Review.
5,380 results